New Fund Offer Updates

Company  Baroda BNP Paribas Asset Management India Pvt. Ltd.
Scheme Name  Baroda BNP Paribas Health and Wellness Fund-Reg(G)
Scheme Type  Open ended scheme
Theme  
Benchmark Index  BSE Health Care - TRI
Fund Manager  Sanjay Chawla
Category  Equity - Sectoral Fund - Pharma & Health Care
Initial Offer Price ()  10
Minimum Investment ()  1000
Additional Investment ()  1000
Objective  The primary objective of the Scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. The Scheme does not guarantee/indicate any returns. However, there can be no assurance that the investment objective of the Scheme will be realized.
Max Entry Load%:  
Max Exit Load%:  0
Option Type  Growth, IDCW

Investment Pattern

TypeMinMax
Equity and equity related instruments of companies in the Pharma & Healthcare and allied sectors80100
Equity and equity related instruments of companies other than above020
Debt & Money Market instruments020
Units issued by REITs & InvITs010
Units of MF (Domestic Schemes)010

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.